Abstract 769P
Background
Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate, has the potential to reduce PK variability and financial expenses. The aim of this study was to investigate equivalence of a boosted, reduced dose of olaparib compared to the non-boosted standard dose.
Methods
This randomized, cross-over, multicenter trial compared the PK of olaparib 300 mg twice daily (BID) followed by olaparib 100 mg BID boosted with the non-therapeutic CYP3A-inhibitor cobicistat 150 mg BID for 7 days, or vice versa, in patients treated with olaparib. Equivalence was defined as a geometric mean ratio (GMR) of area-under-the-curve over one dosing interval (AUC0-12h) and 90% Confidence Interval (CI) within the no-effect boundaries of 0.57-1.25.
Results
Of 15 included patients, 12 were eligible for PK analysis. The AUC0-12h increased with the boosted reduced dose with a GMR of 1.45 (90% CI 1.27-1.65). The maximum plasma concentration was comparable (GMR 0.97; 90%CI 0.84-1.12), and the trough plasma concentration increased (GMR 4.14; 90%CI 3.25-5.27). PK parameters of both therapies are shown in the table. No grade ≥3 adverse events were reported during the study. Table: 769P
Pharmacokinetic parameters of the standard monotherapy and boosted therapy of olaparib. Data are represented as geometric mean (CV%) [confidence interval]
Monotherapy [95%CI] | Boosted therapy [95%CI] | Geometric mean ratio [90%CI] | |
AUC 0-12h (mg*h/L) | 29.4 (46%) [22.2 – 38.9] | 42.7 (41%) [33.2 – 55.1] | 1.45 [1.27 – 1.65] |
C max (mg/L) | 6.37 (37%) [5.07 – 8.00] | 6.19 (28%) [5.19 – 7.39] | 0.97 [0.84 – 1.12] |
T max (h) | 1.25 (66%) [0.85 - 1.83] | 1.67 (42%) [1.30 – 2.16] | 1.34 [1.03 – 1.75] |
C trough (mg/L) | 0.39 (107%) [0.21 – 0.73] | 1.56 (77%) [0.99 – 2.46) | 4.14 [3.25 – 5.27] |
Conclusions
Boosting a 100 mg olaparib dose with the strong CYP3A-inhibitor cobicistat increases olaparib exposure with 45%, compared to the standard dose of 300 mg. Boosting of olaparib is therefore a promising strategy to reduce the olaparib dose. These results encourage a prospective study of boosted olaparib with toxicity-guided dose reductions. If adequate tolerability is established, boosting can lead to a substantial reduction in olaparib therapy costs. Drs. N.A.D. Guchelaar and M.I. Mohmaed Ali have equally contributed to the study.
Clinical trial identification
NCT05078671.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program (grant 10140021910005).
Disclosure
R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. I. Boere: Financial Interests, Institutional, Research Funding: GSK. P. Hamberg: Financial Interests, Personal, Advisory Board: Astellas, MSD, Pfizer, AstraZeneca, BMS, Ipsen. G.S. Sonke: Financial Interests, Research Funding: Merck, Agendia, AstraZeneca, Roche, Novartis; Financial Interests, Speaker, Consultant, Advisor: Novartis, Seattle Genetics, Biovica. N.P. Van Erp: Financial Interests, Institutional, Invited Speaker: Wad'n Workshop; Financial Interests, Institutional, Coordinating PI, IDS: Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11